CyFlow™ CD16 PE-Cy7

CyFlow™ CD16 PE-Cy7
Laser: Blue, Green, Yellow
Target Species: Human, Non-Human Primates
Antigen: CD16
Field of Interest: Immunophenotyping
Clone: 3G8
Regulatory Status: RUO
Alternative Name: FcγRIII
Application: Flow cytometry
Format/Fluorochrome: PE-Cy7
Species of Origin: Mouse
Clonality: monoclonal
Emission Maximum: 785 nm
Excitation Maximum: 496 nm, 565 nm
Isotype: IgG1
Product number: AP596497

For Research Use Only

$285.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA V—WS Code NK80 Concentration Quantity 100 tests Volume 0.4... more
CyFlow™ CD16 PE-Cy7
HLDA WorkshopHLDA V—WS Code NK80
Quantity100 tests
Volume0.4 mL
ImmunogenHuman neutrophils
Background InformationCD16 (FcγRIII) is a 50-65 kDa glycoprotein serving as a low affinity IgG receptor. Human FcγRIII is expressed in two forms - FcγRIIIA and FcγRIIIB. FcγRIIIA is a transmembrane protein of monocytes, macrophages, NK cells and a subset of T cells. It is associated with FcεRI-γ subunit and is responsible for antibody-dependent NK cell cytotoxicity. Mast cell FcγRIIIA is associated, moreover, with FcεRI-β subunit. Besides IgG, FcγRIIIA can be triggered also by oligomeric IgE. FcγRIIIB is a GPI-linked monomeric receptor expressed on neutrophils and is involved in their activation and induction of a proadhesive phenotype.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·> | Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·> | Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA: Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene. Blood. 1998·Apr·1; 91(7):2369‑80. <·PMID:·9516136·> | Zhu X, Hamann KJ, Muňoz NM, Rubio N, Mayer D, Herrnreiter A, Leff AR: Intracellular expression of Fc gamma RIII (CD16) and its mobilization by chemoattractants in human eosinophils. J·Immunol. 1998·Sep·1; 161(5):2574‑9. <·PMID:·9725258·> | Wijngaarden S, van Roon JA, van de Winkel JG, Bijlsma JW, Lafeber FP: Down‑regulation of activating Fcgamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment. Rheumatology·(Oxford). 2005·Jun; 44(6):729‑34. <·PMID:·15757966·> | Komano Y, Nanki T, Hayashida K, Taniguchi K, Miyasaka N: Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis·Res·Ther. 2006; 8(5):R152. <·PMID:·16987426·> | Congy-Jolivet N, Bolzec A, Ternant D, Ohresser M, Watier H, Thibault G: Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa‑158V allotype. Cancer·Res. 2008·Feb·15; 68(4):976‑80. <·PMID:·18281470·> | Choi EI, Wang R, Peterson L, Letvin NL, Reimann KA: Use of an anti‑CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques. Immunology. 2008·Jun; 124(2):215‑22. <·PMID:·18201184·> | Burt BM, Plitas G, Zhao Z, Bamboat ZM, Nguyen HM, Dupont B, DeMatteo RP: The lytic potential of human liver NK cells is restricted by their limited expression of inhibitory killer Ig‑like receptors. J·Immunol. 2009·Aug·1; 183(3):1789‑96. <·PMID:·19587011·> | Jeraiby M, Yahya KS, Depince‐Berger AE, Lambert C: Microbicidal activity measured by flow cytometry: Optimization and standardization for detection of primary and functional deficiencies. J·Immunol·Methods. 2017 Feb 28; 441:8‐14. <·PMID:·27693641·>

Article successfully added.